GLP-1 drugs, originally developed to treat type 2 diabetes and obesity, are showing unexpected benefits against at least 10 other serious health conditions. The FDA has already approved these medications for kidney disease, heart disease, liver disease, and sleep apnea, while early research suggests promise in cancer prevention, asthma, fertility issues, dementia, and substance use disorders .

What Conditions Are GLP-1 Drugs Now Treating?

The class of medications includes semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). These drugs work by mimicking hormones that regulate blood sugar and signal fullness to the brain. Tirzepatide has an added benefit: it acts on a second hormonal pathway called GIP, which may explain why it shows particularly strong effects in some conditions .

The expanding list of approved and studied uses reflects a surprising discovery: these medications do far more than suppress appetite. Researchers are finding that GLP-1 drugs have direct anti-inflammatory and protective effects on multiple organ systems.

• Kidney Disease: A clinical trial with over 3,500 patients showed that semaglutide reduced serious kidney events to 5.8 per 100 patients per year, compared with 7.5 in the placebo group. The FDA approved Ozempic for chronic kidney disease in January 2025, and researchers noted that the kidney protection likely works through multiple mechanisms beyond weight loss .
• Heart Disease: Semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by approximately 20 percent in a major study published in the New England Journal of Medicine. The FDA approved semaglutide for cardiovascular disease in people who are overweight or obese in March 2024 .
• Liver Disease: In a 2025 study, 62.9 percent of patients receiving semaglutide had improved liver inflammation without increased scarring, compared with 34.3 percent in the placebo group. The FDA granted accelerated approval for semaglutide for metabolic liver disease in August 2025 .
• Sleep Apnea: Tirzepatide reduced breathing interruptions during sleep by 25 to 29 per hour, compared with 5 to 6 in the placebo group. Zepbound became the first approved drug for moderate to severe sleep apnea in December 2024 .
• Joint Pain: Patients with obesity and knee osteoarthritis reported a 41.7 percent reduction in knee pain with semaglutide, compared with 27.5 percent with placebo, after 68 weeks of treatment .

Can GLP-1 Drugs Help Reduce Addiction and Substance Use?

One of the most striking findings involves substance use disorders. A large study of over 600,000 American veterans with type 2 diabetes, published in the BMJ, found that GLP-1 use was linked to a 14 percent lower risk of developing addiction to alcohol, cannabis, cocaine, nicotine, and opioids . Among veterans with preexisting substance use disorders, GLP-1 use was linked to fewer drug-related emergency visits, hospitalizations, overdoses, and deaths over three years.

A separate study published in JAMA Psychiatry in February 2025 confirmed these findings, showing that patients with alcohol use disorder drank less and had fewer cravings for alcohol and cigarettes during treatment with semaglutide .

"Patients with rheumatoid arthritis experiencing strong anti-inflammatory effects without losing weight," noted Daniel Drucker, an endocrinologist at the University of Toronto who has studied GLP-1 drugs for decades.

Daniel Drucker, Endocrinologist at the University of Toronto

What Early Research Shows About Cancer, Asthma, and Fertility?

While not yet approved for these conditions, researchers are investigating GLP-1 drugs for several other serious health issues. A study published in JAMA Oncology in December 2024 examined 101.2 million patient records and found that people with type 2 diabetes who took GLP-1 drugs had a markedly reduced risk of colon cancer. Laboratory experiments show that GLP-1 drugs can reduce cancer cell migration and tumor growth, though researchers emphasized that the link is strong enough to warrant further study .

A British study published in April 2025 examined approximately 60,000 patients, of whom roughly 10,000 used GLP-1 drugs and had both obesity and asthma. The patients had better symptom control, and researchers believe the drugs' anti-inflammatory effects may be behind the improvements .

For fertility issues, a study published in the Journal of Clinical Medicine in September 2023 found that low doses of semaglutide reduced body weight in nearly 80 percent of patients with polycystic ovary syndrome who had not responded to previous treatment, and menstrual cycles normalized in these patients. There are also signs that weight loss linked to semaglutide may increase sperm count and sperm motility in men .

How Do GLP-1 Drugs Actually Work in the Brain?

Clinical trials have consistently shown that GLP-1 drugs reduce appetite, cravings, and intrusive thoughts about food. Brain imaging studies show reduced activity in the brain's reward centers when exposed to high-calorie food. In an 18-week study published in Diabetes in June 2023, adults with obesity taking tirzepatide showed clearly reduced hunger and fewer cravings .

This neurological effect may explain why the drugs work for conditions beyond weight loss. By reducing reward-seeking behavior and inflammation throughout the body, GLP-1 drugs appear to address root causes of multiple chronic diseases.

Steps to Understanding Your GLP-1 Options

• Consult Your Doctor About Your Specific Condition: GLP-1 drugs are approved for different conditions, and your doctor can determine whether you qualify based on your health status, not just your weight. Some insurers may cover the medication if you have an approved condition like kidney disease or heart disease, even if weight loss is also a benefit.
• Ask About Insurance Coverage and Alternatives: Coverage for GLP-1 drugs has become increasingly restrictive, with many insurers requiring additional criteria or lifestyle programs before approval. Understanding your plan's specific requirements can help you prepare documentation and avoid surprise denials.
• Discuss Long-Term Treatment Plans: Research shows that many people need to stay on GLP-1 drugs long-term to maintain benefits. Talk with your doctor about what ongoing treatment would look like, including costs and potential side effects, so you can make an informed decision.

What Does This Mean for the Future of Weight Loss Treatment?

The expanding evidence for GLP-1 drugs beyond weight loss is reshaping how doctors think about obesity itself. Rather than viewing obesity as simply a cosmetic or lifestyle issue, researchers increasingly see it as a systemic disease that contributes to multiple organ system failures. By treating obesity, GLP-1 drugs may prevent or reverse damage to the heart, kidneys, liver, and joints .

However, access remains a major challenge. Insurance coverage for weight-loss-specific GLP-1 drugs became "more restrictive" in 2026, with the number of people without commercial insurance coverage for Novo Nordisk's Wegovy jumping by 42 percent from 2025 to 2026, and coverage for Eli Lilly's Zepbound increasing by 12 percent during the same period . Over 16 million people with private insurance don't have any coverage for this class of drug in 2026 when prescribed for weight loss .

One patient, Kristi Turner, lost 108 pounds on Zepbound with a $25 copay through her husband's employer insurance. In January 2025, her coverage disappeared because she didn't have diabetes, according to documents reviewed by Business Insider. Her insurer offered only one path to restore coverage: a six-month program of diet counseling, physical therapy, mental health check-ins, and lab tests, with no guarantee of approval . Turner now pays around $500 a month out of pocket to stay on the medication.

"We have the same disease. We're just at different points," Turner said, noting that her husband kept his coverage for Mounjaro because he has type 2 diabetes.

Kristi Turner, Zepbound Patient

As GLP-1 drugs continue to show benefits across multiple conditions, the gap between what medicine can do and what insurance will cover is widening. Patients, doctors, and researchers are calling for more equitable access to these potentially life-changing medications.